Pfizer provided an update on the progression of clinical programs in its high-priority therapeutic areas, and announced the start of Phase III trials for two new molecular entities. Earlier this year, Pfizer started Phase III studies in JAK inhibitor (CP-690,550), an orally-administered, disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The company is also conducting Phase III trials with tanezumab, a fully-humanized monoclonal antibody targeting nerve growth factor. Tane...